Which groundbreaking legislation fundamentally transformed pharmaceutical pricing strategies by creating financial incentives for companies to develop medications for rare diseases affecting fewer than 200,000 patients?

The pharmaceutical industry's pricing strategies have evolved dramatically over the decades, particularly for rare disease treatments. This poll explores a critical turning point in pharmaceutical pricing history that changed how companies approach drug development for rare conditions. Test your knowledge about how policy changes transformed the economics of treating uncommon diseases and created an entirely new market segment in medicine.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

The Orphan Drug Act of 1983
The Hatch-Waxman Act of 1984
The Prescription Drug Marketing Act of 1987
The Drug Price Competition Act of 1992